financetom
Business
financetom
/
Business
/
Brilliant Earth Group's Q3 sales rise 10%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Brilliant Earth Group's Q3 sales rise 10%
Nov 5, 2025 4:17 AM

Overview

* Brilliant Earth ( BRLT ) Q3 net sales grow 10% yr/yr

* Company, which deals with ethically sourced fine jewelry, achieves 57.6% gross margin, consistent with medium-term target

* Brilliant Earth ( BRLT ) reports 17th consecutive quarter of positive adjusted EBITDA

Outlook

* Brilliant Earth ( BRLT ) expects full-year net sales growth of 3% to 4.5%

* Company anticipates full-year adjusted EBITDA margin of 2% to 3%

* Brilliant Earth ( BRLT ) confident in strong consumer demand entering holiday season

Result Drivers

* ENGAGEMENT RINGS - Return to bookings growth in engagement rings with increased average selling price

* FINE JEWELRY - 45% year-over-year bookings growth in fine jewelry

* GROSS MARGIN - Achieved 57.6% gross margin despite high metal prices and tariffs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $110.30 $108.59

mln mln (6

Analysts

)

Q3 Net -$700,00

Income 0

Q3 $3.60

Adjusted mln

EBITDA

Q3 Gross 57.60%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the apparel & accessories retailers peer group is "buy."

* Wall Street's median 12-month price target for Brilliant Earth Group Inc ( BRLT ) is $2.20, about 16.4% below its November 4 closing price of $2.56

* The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 26 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
Feb 21, 2025
(Reuters) - Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in pre-launch inventory in its financial statements, a filing showed on Wednesday. The move is unusual as it comes more than a year before the drug, orforglipron, is expected to be launched. Most drugmakers...
Citigroup, HSBC, Morgan Stanley, Royal Bank of Canada Fined $132 Million Over UK Bond Trading
Citigroup, HSBC, Morgan Stanley, Royal Bank of Canada Fined $132 Million Over UK Bond Trading
Feb 21, 2025
06:09 AM EST, 02/21/2025 (MT Newswires) -- Citigroup ( C ) , HSBC (HSBC), Morgan Stanley (MS), and Royal Bank of Canada ( RY ) have been ordered to pay a total of 104.5 million British pounds ($132.3 million) in fines by April 22 to settle accusations of traders inappropriately sharing competitively sensitive information about the pricing of UK bonds,...
Tesla recalls 380,000 vehicles in US over power steering assist issue
Tesla recalls 380,000 vehicles in US over power steering assist issue
Feb 21, 2025
Feb 21 (Reuters) - Tesla said on Friday it was recalling nearly 380,000 vehicles in the United States due to a power steering assist failure that could increase steering effort, particularly at low speeds, potentially raising the risk of a crash. The recall follows a more than one-year-long probe by the National Highway Traffic Safety Administration after some Tesla owners...
Teva Pharma and Alvotech launch Stelara biosimilar in US
Teva Pharma and Alvotech launch Stelara biosimilar in US
Feb 21, 2025
Feb 21 (Reuters) - Teva Pharmaceuticals and Alvotech ( ALVO ) said on Friday they have launched a biosimilar to Johnson & Johnson's ( JNJ ) autoimmune disease drug Stelara in the United States. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved